176 related articles for article (PubMed ID: 20876369)
1. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.
Marcos LA; Camins BC
Antimicrob Agents Chemother; 2010 Dec; 54(12):5376-8. PubMed ID: 20876369
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
3. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia.
Swartz TH; Huprikar S; Labombardi V; Pinney S; Anyanwu A; Lee M; Patel G
Transpl Infect Dis; 2013 Oct; 15(5):E177-81. PubMed ID: 23902131
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
[TBL] [Abstract][Full Text] [Related]
6. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
7. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
Xiong YQ; Abdelhady W; Tang C'; Bayer AS
J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
10. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
[TBL] [Abstract][Full Text] [Related]
11. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization.
Andrade-Baiocchi S; Tognim MC; Baiocchi OC; Sader HS
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):149-52. PubMed ID: 12614988
[TBL] [Abstract][Full Text] [Related]
12. VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin.
Saravolatz LD; Pawlak J
Diagn Microbiol Infect Dis; 2019 Feb; 93(2):159-161. PubMed ID: 30366652
[TBL] [Abstract][Full Text] [Related]
13. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
14. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.
Smith K; Gemmell CG; Lang S
Eur J Clin Microbiol Infect Dis; 2013 Oct; 32(10):1327-32. PubMed ID: 23624635
[TBL] [Abstract][Full Text] [Related]
15. Pacemaker lead endocarditis.
Singh P; Tandon R; Kumbkarni S; Ralhan S; Mohan B; Wander GS
J Assoc Physicians India; 2012 Mar; 60():50-1. PubMed ID: 22799116
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon JL; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
19. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
